|Bid||0.00 x 2200|
|Ask||0.00 x 1800|
|Day's Range||1.99 - 2.16|
|52 Week Range||1.93 - 8.30|
|Beta (3Y Monthly)||0.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Tyme Technologies, Inc. (TYME), a clinical stage biotechnology company developing cancer therapeutics for pancreatic, prostate and sarcoma tumors, today announced that it will be featured as a presenting company at the Stifel 2018 Healthcare Conference. The conference is being held on November 13-14, 2018 at the Lotte New York Palace Hotel in New York. The presentation will be webcast live. To access the webcast, please visit the Company’s website, https://ir.tymeinc.com/events-and-presentations or http://wsw.com/webcast/stifel14/tyme/. The webcast replay will remain available for 90 days following the live presentation. Tyme Technologies, Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.
Tyme Technologies, Inc. (TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal quarter ended September 30, 2018. The Company’s lead clinical program, SM-88, is currently being evaluated in ongoing Phase II clinical trials for metastatic pancreatic cancer and biomarker recurrent prostate cancer.
Tyme Technologies Inc, (TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced the appointment of former Kite Pharma and Celgene executive, Michele Korfin as the Company’s Chief Commercial Officer. Ms. Korfin has over 20 years of experience in oncology, focused on product launches, oncology marketing strategy, commercial sales, market access and government affairs.
Tyme Technologies, Inc. (TYME) announced today an agreement to include SM-88 as an experimental arm in the novel Precision Promise adaptive Phase II/III trial platform sponsored by PanCAN. The objective of Precision Promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, industry and regulatory entities.
Tyme Technologies, Inc. (TYME) today announced that JAF will provide funding and patient support for an investigator-initiated Phase II trial of SM-88 in patients with previously treated metastatic Ewing’s sarcoma. During our compassionate use program, two third-line refractory metastatic Ewing’s sarcoma patients were treated with SM-88 and, based on available data through February 2018, both achieved complete or partial RECIST responses with no drug-related serious adverse events. The trial will be conducted by Dr. Sant Chawla, a world-recognized leader in the treatment and clinical study of sarcomas. He has been an author for over 100 peer-reviewed publications and books as well as a frequent presenter at the American Society of Clinical Oncology. Dr. Chawla founded The Sarcoma Oncology Research Center in Santa Monica and is on the clinical faculty of numerous cancer centers, including UCLA, USC, Stanford, the John Wayne Cancer Institute, and M.D. Anderson. The Sarcoma Oncology Research Center is also currently participating in Tyme’s Phase II trial in metastatic pancreatic cancer.
NEW YORK, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Douglas A. Michels to the Company’s board of directors, effective October 1, 2018. Mr. Michels, 62, is a pioneer in the adoption of new clinical technologies, as well as a proven executive at both large and small healthcare organizations. Mr. Michels most recently served as President and Chief Executive Officer of OraSure Technologies, Inc. and a member of the OraSure board of directors from June 2004 to March 2018. During his tenure, OraSure commercialized multiple new products, grew annual sales to over $160 million and a market capitalization of approximately $350 million in 2003 to $1.1 billion at the end of 2017.
Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Director, Mid Atlantic Region. An experienced life science executive and former investment banker, Mr. Dickey will direct the firm’s strategy and service to clients in the region’s fast-growing life science clusters. “Danforth has assembled a first-rate team with deep expertise in accounting, finance strategy and operations for life science companies, allowing both start-ups and growth-stage clients to benefit from the highest level of talent in a flexible and capital-efficient way,” said Mr. Dickey.
NEW YORK, Sept. 05, 2018-- Tyme Technologies, Inc., today announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion ...
Tyme Technologies, Inc. (TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will be featured as a presenting company at the Rodman & Renshaw 20th Annual Global Investment Conference. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York. The presentation will be webcast live. To access the webcast, please visit the Company’s website, https://ir.tymeinc.com/events-and-presentations, or (http://wsw.com/webcast/rrshq28/tyme/). The webcast replay will remain available for 90 days following the live presentation.
Stock Monitor: Cerus Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 16, 2018 / Active-Investors.com has just released a free research report on Tyme Technologies, Inc. (NASDAQ: TYME ). If you ...